IVG-PREMIUM-E-LIQUIDS
25.3.2019 10:04:10 CET | Business Wire | Press release
IVG Premium E-Liquids, the UK’s market-leading brand, has announced a strategic partnership with globally renowned Kollaras & Co – A 3rd generation, family owned and operated business. Kollaras & Co specialises in supporting independent retailers across multiple channels in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005029/en/
Kollaras & Co have landed the master distribution rights for IVG products within Australia, which will allow vapers from down under to join vapers from over 60 countries and 6 continents that vape premium British flavours from IVG.
John Kollaras, Managing Director of Kollaras & Co, commented that the alliance was an important step for the near 60-year-old business, commenting “We are thrilled to partner with IVG, as we continue to strive to provide a unique offering within our portfolio, and cement our position as a dynamic solutions provider.” Kollaras continued: “Quality, authenticity and passion are three key values which we look for in partners, and IVG is no exception to this.”
Ahsan Bawa, CEO of IVG, commented that “Our incredible journey continues here at IVG, our multi international and award winning brand continues to reach new heights. We are proud and honoured to welcome the Kollaras family into our own, and this strategic alliance will help in those efforts on delivering IVG to a store near you. We are thrilled to officially announce the partnership with Kolloras & Co, a key step for Oceania & South Pacific regions
Kollaras & Co will be distributing 26 delicious e-liquid flavours in 60 ML and 10 ML from IVG Premium E-Liquids’ into the Australia retail market sector by the end of April 2019.
13 International Accolades “Leading E-Liquids Specialist 2019”, Best Sweet Flavour, and more have played a key role in the Australia company taking the products on board, along with the existing reviews of the vape enthusiasts in the Australian market.
Kollaras closed by adding “Our core innovation metrics focus on creating brands that are valued by our customers and deliver outstanding value to their shoppers, and IVG is a fantastic example of this. We are both confident and excited about the partnership and our growth prospects in the year ahead to say the least!”
About IVG Premium E-Liquids - www.ivgeliquids.co.uk
About Kollaras & Co: www.kollaras.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005029/en/
Contact:
Media Contact: Deepika Patel Head of Marketing +44 (0) 1772 217000 deepika.patel@ivgeliquids.com
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom